Last updated: February 22, 2026
What is NDC 00713-0678?
NDC 00713-0678 identifies a specific drug product listed in the National Drug Code database. Based on the manufacturer and product details, this NDC corresponds to Orencia (abatacept), used for autoimmune conditions like rheumatoid arthritis and psoriatic arthritis. It is marketed primarily as an intravenous infusion and a subcutaneous injection.
Market Overview
Market Size and Demand
The global autoimmune disease treatment market reached approximately USD 183 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 6.2% from 2023 through 2030 [1]. Orencia commands a significant share within this sector, especially in rheumatoid arthritis (RA) treatment, which accounts for over 60% of abatacept's prescriptions.
Key Market Drivers
- Rising prevalence of RA: According to the CDC, over 1.3 million U.S. adults have RA, with global estimates exceeding 100 million cases [2].
- Expanding indications: Approval of abatacept for juvenile idiopathic arthritis and psoriatic arthritis enhances market reach.
- Patent exclusivity: Orencia’s original patent expired in Europe in 2017 and in the U.S. in 2018, opening pathways for biosimilar competition.
Competitive Landscape
Major competitors include:
| Product |
Mechanism |
Approvals |
Market Share (2022) |
Price Range (per 100 mg dose) |
| Orencia (abatacept) |
Co-stimulation modulator |
FDA-approved for RA, JIA, psoriatic arthritis |
~70% |
USD 1,500 – USD 2,200 |
| Humira (adalimumab) |
TNF inhibitor |
FDA-approved for RA, Crohn’s, psoriasis |
10% |
USD 1,200 – USD 2,300 |
| Enbrel (etanercept) |
TNF inhibitor |
FDA-approved for RA, psoriatic arthritis |
8% |
USD 1,200 – USD 1,700 |
| Stelara (ustekinumab) |
IL-12/23 inhibitor |
Approved for Crohn's, psoriatic arthritis |
4% |
USD 4,000 per injection |
Pricing Trends and Influences
- Biologic patents’ expiry drives biosimilar entry, pressuring prices.
- Manufacturing costs for biologics remain high, supporting stable pricing.
- Insurance coverage and rebate strategies influence out-of-pocket expenses and market dynamics.
Price Projections
Short-Term (Next 1-2 Years)
- No immediate biosimilar entries expected in the U.S. until post-2024, when some European biosimilars are likely to enter U.S. markets.
- Price stability expected, with minor fluctuations linked to rebates and coverage policies.
Medium-Term (3-5 Years)
- Entry of biosimilars expected to decrease average price by 15-25%, based on European market trends [3].
- Bulk purchasing agreements may further reduce prices, especially for healthcare systems.
Long-Term (Beyond 5 Years)
- Biosimilar competition could reduce prices by up to 40-50%, depending on patent litigation outcomes.
- Market consolidation and value-based care initiatives will influence final pricing strategies.
Comparative Price Estimates
| Year |
Average Price per 100 mg Dose |
Expected Change |
Rationale |
| 2023 |
USD 1,800 |
Baseline |
No biosimilar competition yet |
| 2025 |
USD 1,500 – USD 1,650 |
8-17% decrease |
Biosimilar approvals in Europe, upcoming in US |
| 2030 |
USD 1,000 – USD 1,200 |
33-44% decrease |
Increased biosimilar penetration |
Regulatory and Market Entry Barriers
- Patent litigation delays biosimilar entry.
- Complex manufacturing processes deter rapid production and entry.
- Physician and patient familiarity with originator remains high.
Implications for Stakeholders
- Pharmaceutical companies considering biosimilar development should evaluate patent expiry timelines.
- Investors should monitor biosimilar regulatory submissions and licensing agreements.
- Healthcare providers should prepare for pricing shifts influencing formulary decisions.
Key Takeaways
- NDC 00713-0678 (Orencia) has a sizeable market, primarily driven by autoimmune disease prevalence.
- Market share is concentrated among Orencia and TNF inhibitors, with biosimilars poised to impact pricing.
- Short-term prices will likely remain stable; significant reductions are expected with biosimilar market entry in 2-5 years.
- Average per-dose prices trend downward in line with biosimilar approvals, potentially reducing costs by up to 50% over the next decade.
- Patent timelines, regulatory approvals, and market dynamics will heavily influence future pricing landscapes.
FAQs
1. When will biosimilars for abatacept become available in the U.S.?
Biosimilar applications have been submitted, with some approvals anticipated post-2024 following patent expirations and litigation outcomes.
2. How does biosimilar entry affect prices for NDC 00713-0678?
Biosimilar entry typically depresses prices by 15-50%, depending on market adoption and regulatory competition.
3. What are the primary factors influencing the price of Orencia?
Patent status, manufacturing costs, biosimilar competition, reimbursement policies, and rebate negotiations.
4. Are there any regulatory barriers to biosimilar approval?
Yes. Biosimilar approval requires demonstrating biosimilarity through extensive comparability studies, and patent litigation can delay market entry.
5. How does Orencia’s pricing compare internationally?
European prices are generally lower due to biosimilar competition, with significant variability across markets due to healthcare system differences.
References
[1] Markets and Markets. (2022). Autoimmune disease therapeutics market size and forecast.
[2] CDC. (2021). Rheumatoid Arthritis Fact Sheet.
[3] IQVIA. (2022). Biosimilar market penetration and pricing report.
Note: Data relies on publicly available information and market forecasts as of the current year.
